NPS PHARMACEUTICALS TO PROMOTE ALLERGAN'S RESTASIS TO RHEUMATOLOGISTS IN THE UNITED STATES

NPS Pharmaceuticals, Inc. announced today that it has executed an agreement with Allergan, Inc. to promote RESTASIS(R) (cyclosporine ophthalmic emulsion 0.05%), the first and currently only prescription eye drop to increase tear production in patients with chronic dry eye disease (keratoconjunctivitis sicca), a common condition characterized by insufficient tear production to lubricate the eye. Chronic dry eye disease frequently affects patients with autoimmune disorders.

Finanzen.net (http://finanzen.net/news/news_detail.asp?NewsNr=344530)